Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 4/20 | 0.45 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838083 | 0.86 | PRKCZ (0.61) | PRKCZALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL8188234 | 0.85 | KMT2A (0.65) | PRKCZALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3976339 | 0.84 | PRKCZ (0.58) | PRKCZALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1799330 | 0.84 | KMT2A (0.69) | PRKCZALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2369108 | 0.83 | PRKCZ (0.63) | PRKCZALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL6925391 | 0.83 | PRKCZ (0.51) | PRKCZALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL13926190 | 0.83 | PRKCZ (0.51) | PRKCZALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2368512 | 0.83 | PRKCZ (0.68) | PRKCZALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL13926187 | 0.83 | ALDH1A1 (0.70) | PRKCZALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL28599809 | 0.83 | PRKCZ (0.48) | PRKCZALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012100732-A1 | RETINOID-RELATED ORPHAN RECEPTOR GAMMA MODULATORS, COMPOSITION CONTAINING THEM AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2012-08-02 | — | — | WO | disclosed |
| US-8193215-B2 | Thieno[2 3-b]pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| US-8022076-B2 | Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents | XENTION LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | XENTION LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| CN-101351453-A | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2009-01-21 | — | — | CN | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| CN-1823071-A | Thienopyrimidine derivatives as potassium channel inhibitors | XENTION DISCOVERY LTD (GB) | 2006-08-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | SCN8A, SCN1B, SCN2B | PRKCZ 3485/4885ALDH1A1 3155/4885HPGD 2337/4885 |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | PRKCZ 874/4885ALDH1A1 772/4885HPGD 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.